Skip to content
Screener

Becton, Dickinson and Company BDX Connected Care — Research and development expense

Other segment segments

Medical
$523M+17.0%
Interventional
$72M+14.3%
Medical Essentials
$53M+10.4%
BioPharma Systems
$17M-5.6%

Similar metrics at other companies

The Cooper Companies, Inc. logo
COOCooperSurgical — Research and development expense
$20.4M+2.5%
The Cooper Companies, Inc. logo
COOCooperVision — Research and development expense
$22.1M-13.7%
TechnipFMC logo
FTISubsea — Research and development expense
$16.7M-8.7%
Enovis logo
ENOVReconstructive — Research and development expense
$23.98M+14.0%
Gevo logo
GEVOGevoND — Research and development expense
$0
DBV Technologies logo
DBVTExpenses by function — Research and development expense
$9.4M+64.9%

Other financials

Income statement

See full
Revenue$5.0B-9.5%
Gross profit$2.3B-12.1%
Operating income$663.0M-24.8%
Net income$377.0M-34.3%
EPS (diluted)$1.64-18.0%

Balance sheet

See full
Cash & equivalents$708.0M-11.3%
Total debt$13.5B-22.9%
Total equity$24.4B-4.1%
Total assets$50.7B-7.6%

Cash flow

See full
Operating cash flow$776.0M-51.1%
CapEx$143.0M-24.3%
Free cash flow$633.0M-54.7%

Valuation

See full
Market cap$47.02B-4.8%
Enterprise value$59.83B-9.6%
P/E50×+18.8×
P/S2.3×-0.1×

Profitability

See full
Gross margin46.4%+1.7pp
Operating margin9.6%-1.7pp
Net margin4.5%-3.2pp
FCF margin13.1%

Returns & leverage

See full
Return on equity3.8%-2.4pp
Debt / equity0.6×-0.1×
Current ratio0.9×-0.2×

Where this comes from

Reported directly by Becton, Dickinson and Company in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Becton, Dickinson and Company’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:34 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000010795-26-000026
Three Months Ended March 31, 2026 / (Millions of dollars)Medical / EssentialsConnected / CareBio Pharma / SystemsInterventionalTotal
% of revenues50.7%43.7%53.6%31.6%
Selling and administrative expense18519032277684
% of revenues11.2%17.0%5.4%20.4%
Research and development expense53901772232
% of revenues3.2%8.1%2.8%5.3%
Other operating expense, net33
% of revenues0.3%
Segment Operating Income$574$347$225$579$1,724

Item 1. Financial Statements (Unaudited)

FAQ

What is Becton, Dickinson and Company's connected care — research and development expense?
Becton, Dickinson and Company (BDX) reported connected care — research and development expense of $90M in Q1 2026.
What does connected care — research and development expense mean?
This metric tracks the investment in research and development activities specifically dedicated to the Connected Care segment. It includes costs for new product innovation, software development, and clinical validation of new technologies.

Ask your AI about Becton, Dickinson and Company's connected care — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude